Companies: 10,795·Total market cap: $144.5T
Mesoblast Limited

Mesoblast Limited

MEOBFOTCHealthcare● Active
$1.55
$-0.15(-8.82%)
Market Cap$2.0B
P/E Ratio
52W High$2.59
52W Low$0.96
Overview

Mesoblast Limited(MEOBF)股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

meobf · 股价预测 · 9 位分析师(近3月)· FMP · 更新于 2026年6月9日

分析师评级与共识

基于过去 3 个月内 9 位华尔街分析师

SellBuy

Hold

9 位分析师

共识

评级分布

Strong Buy
0
Buy
3
Hold
4
Sell
2
Strong Sell
0
合计: 9 · 买入占比: 33.3%

12 个月目标价

High

$0.00

Consensus

$0.00

+0.0% upside

Low

$0.00

Median: $0 · Last Close: $1.55

Mesoblast Limited(MEOBF)的分析师共识为 Hold,基于过去 3 个月内 9 位华尔街分析师的评级。MEOBF 的 12 个月平均目标价为 $0.00,相对当前价 $1.55 代表 +0.0% 的潜在上行空间。

短期股价预测

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-10$1.540.33%

1-day model range: $1.54–$1.55. Peak: $1.55 (-0.33%).

长期股价预测

⚠️ 在满 252 个交易日历史(IPO/上市时间较短)前不展示长期预测;短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号(SMA×6 + EMA×6 + RSI + MACD)· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

7%14%79%
1Buy
2Neutral
11Sell
RSI (14)0.0Oversold
MACDBEARISH

Refreshes daily from EOD close

Moving Averages · MEOBF · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$1.67SELL
MA 10$1.68SELL
MA 20$1.69SELL
MA 50$1.67SELL
MA 100$1.62SELL
MA 200$0.00NEUTRAL
Current $MEOBF · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$1.65SELL
EMA 10$1.67SELL
EMA 20$1.68SELL
EMA 50$1.67SELL
EMA 100$1.66SELL
EMA 200$0.00NEUTRAL
Current $MEOBF · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
Cantor Fitzgerald2023-09-20
Maintains
OverweightOverweight
Cantor Fitzgerald2023-08-30
Maintains
OverweightOverweight
Jefferies2023-08-30
Upgrade ↑
HoldBuy
Maxim Group2023-08-06
Downgrade ↓
BuyHold
Chardan Capital2023-08-03
Maintains
SellSell
William Blair2023-08-03
Downgrade ↓
OutperformMarket Perform
Piper Sandler2023-08-03
Downgrade ↓
OverweightNeutral
Chardan Capital2023-05-29
Maintains
SellSell
Jefferies2022-12-05
Downgrade ↓
BuyHold
Chardan Capital2022-06-02
Maintains
SellSell

Wall Street analysts have recently issued updated ratings on Mesoblast Limited (MEOBF) stock. Of the recent 21 rating actions, 2 were upgrades and 10 were downgrades. 9 analysts currently cover MEOBF.

分析师推荐趋势

Buy ratings01↑ +1
Hold ratings00
Sell ratings101

MEOBF analyst recommendation trends show increasing buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 1 per month.

财务预测:EPS 与营收一致预期

Revenue This Year

$123M

↓ 59.2% YoY

Revenue Next Year

$200M

↑ 61.9% YoY

EPS This Year

$-0.03

EPS Next Year

$0.01

↓ 119.7% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast MEOBF EPS of $-0.03 for the current fiscal year, based on estimates from 1 analysts. The MEOBF revenue forecast is $123M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

MEOBF 股价预测由两类独立数据源支撑:来自 9 位华尔街分析师(S&P Global / FMP)的共识评级,以及基于历史日终价计算的技术分析。MEOBF 的共识目标价为 $0.00(+0.0% 上行空间),分析师共识为 Hold。

MEOBF 的短期预测(明日)为 $1.54(-0.33%)。

Mesoblast Limited 在 OTC 上市,代码 MEOBF。MEOBF 在 2027 年的整体展望偏中性/分化,在覆盖分析师中约 33% 对应 Hold 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

MEOBF 预测 · 8 个问题

根据 9 位华尔街分析师,MEOBF 的 12 个月平均目标价为 $0.00,最高 $0.00、最低 $0.00。若有图表,中位目标价可在上方查看。相对当前价 $1.55,隐含约 +0.0% 的上行空间。

MEOBF 目标价MEOBF 分析师目标价MEOBF 12个月目标价目标价 MEOBF

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.